AU2019214347B2 - Glass formulations comprising steroid dimers and uses thereof - Google Patents

Glass formulations comprising steroid dimers and uses thereof Download PDF

Info

Publication number
AU2019214347B2
AU2019214347B2 AU2019214347A AU2019214347A AU2019214347B2 AU 2019214347 B2 AU2019214347 B2 AU 2019214347B2 AU 2019214347 A AU2019214347 A AU 2019214347A AU 2019214347 A AU2019214347 A AU 2019214347A AU 2019214347 B2 AU2019214347 B2 AU 2019214347B2
Authority
AU
Australia
Prior art keywords
steroid
linear
branched
implant
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2019214347A
Other languages
English (en)
Other versions
AU2019214347A1 (en
Inventor
Kyle Battiston
Hans Christian FISCHER
Dimitra LOUKA
Wendy Alison NAIMARK
Ian Charles PARRAG
J. Paul Santerre
Matthew Alexander John STATHAM
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ripple Therapeutics Corp
Original Assignee
Ripple Therapeutics Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ripple Therapeutics Corp filed Critical Ripple Therapeutics Corp
Publication of AU2019214347A1 publication Critical patent/AU2019214347A1/en
Application granted granted Critical
Publication of AU2019214347B2 publication Critical patent/AU2019214347B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/554—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being a steroid plant sterol, glycyrrhetic acid, enoxolone or bile acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6953—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a fibre, a textile, a slab or a sheet
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts or implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0092—Hollow drug-filled fibres, tubes of the core-shell type, coated fibres, coated rods, microtubules or nanotubes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5089—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5192—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7007—Drug-containing films, membranes or sheets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/54—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
    • C07J7/001—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group
    • C07J7/004—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group substituted in position 17 alfa
    • C07J7/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group substituted in position 17 alfa substituted in position 16
    • C07J7/0055—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group substituted in position 17 alfa substituted in position 16 by a saturated or unsaturated hydrocarbon group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Botany (AREA)
  • Neurosurgery (AREA)
  • Transplantation (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
AU2019214347A 2018-02-02 2019-02-01 Glass formulations comprising steroid dimers and uses thereof Active AU2019214347B2 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201862625460P 2018-02-02 2018-02-02
US62/625,460 2018-02-02
US201862627608P 2018-02-07 2018-02-07
US62/627,608 2018-02-07
US201862758234P 2018-11-09 2018-11-09
US62/758,234 2018-11-09
PCT/CA2019/050135 WO2019148293A1 (en) 2018-02-02 2019-02-01 Glass formulations comprising steroid dimers and uses thereof

Publications (2)

Publication Number Publication Date
AU2019214347A1 AU2019214347A1 (en) 2020-08-20
AU2019214347B2 true AU2019214347B2 (en) 2023-09-28

Family

ID=67479137

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019214347A Active AU2019214347B2 (en) 2018-02-02 2019-02-01 Glass formulations comprising steroid dimers and uses thereof

Country Status (9)

Country Link
US (9) US11612567B2 (https=)
EP (1) EP3740494A4 (https=)
JP (1) JP7502186B2 (https=)
KR (1) KR102952719B1 (https=)
CN (1) CN111971292B (https=)
AU (1) AU2019214347B2 (https=)
CA (1) CA3087898A1 (https=)
MX (1) MX2020008017A (https=)
WO (3) WO2019148291A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111971292B (zh) 2018-02-02 2024-12-13 波纹疗法公司 包含类固醇二聚体的玻璃制剂及其用途
WO2020154815A1 (en) 2019-02-01 2020-08-06 Ripple Therapeutics Corporation Crystalline forms of dexamethasone dimers and uses thereof
CN114599406A (zh) * 2019-07-10 2022-06-07 波纹疗法公司 包含二聚类固醇前药的表面涂层和可植入装置及其用途
JP2022541341A (ja) * 2019-07-25 2022-09-22 リップル セラピューティクス コーポレーション ステロイド二量体を含む物品と治療剤の送達におけるそれらの使用
WO2021024041A1 (en) 2019-08-07 2021-02-11 Ripple Therapeutics Corporation Controlled release drug dimers
CN111485325A (zh) * 2020-04-16 2020-08-04 青岛科技大学 一种耐高温的抗菌纳米纤维无纺布及其制备方法和用途
MX2022013665A (es) 2020-05-01 2022-11-30 Ripple Therapeutics Corp Composiciones y metodos heterodimeros para el tratamiento de trastornos oculares.
EP4108231A1 (en) 2021-06-25 2022-12-28 Johann-Wolfgang-Goethe-Universität Frankfurt am Main In-situ dissolving electrospun polymer fibers for ocular drug delivery
WO2023079362A1 (en) * 2021-11-03 2023-05-11 Ripple Therapeutics Corporation Processable compositions and use for the same
US20260007686A1 (en) * 2022-07-12 2026-01-08 Ripple Therapeutics Corporation Compositions and methods for improving vision
AU2024238803A1 (en) * 2023-03-23 2025-10-09 Praesidia Biotherapeutics Inc. Prodrugs, prodrug compositions and related methods
TR2024002978A1 (tr) * 2024-03-12 2025-09-22 İstanbul Tekni̇k Üni̇versi̇tesi̇ Elektroeği̇rme yöntemi̇yle elde edi̇len ve i̇laç yüklü bi̇yopoli̇mer nanoli̇flerle kaplanan göz i̇mplanti üreti̇m yöntemi̇

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3663579A (en) * 1968-05-03 1972-05-16 Hoechst Ag Dimeric steroid-21-alkyl-carbonates and process for their manufacture
US20030118528A1 (en) * 2001-11-19 2003-06-26 Walters Kenneth A. Topical delivery of codrugs
WO2010062562A1 (en) * 2008-10-27 2010-06-03 The Trustees Of The University Of Pennsylvania Synthesis and use of cationic steroids for anti-inflammatory drug therapy

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1058886A (en) 1910-04-13 1913-04-15 Alfred Mueller Firing mechanism for firearms.
FR7604M (https=) 1968-04-22 1970-01-19
US4024871A (en) 1975-07-23 1977-05-24 Ethicon, Inc. Antimicrobial sutures
WO2001007657A1 (en) 1999-07-27 2001-02-01 Phylos, Inc. Peptide acceptor ligation methods
US4532316A (en) 1984-05-29 1985-07-30 W. L. Gore & Assoc., Inc. Phase separating polyurethane prepolymers and elastomers prepared by reacting a polyol having a molecular weight of 600-3500 and isocyanate and a low molecular weight chain extender in which the ratios of reactants have a limited range
PL257230A1 (en) 1985-12-31 1988-03-03 Zaklad Polimerow Pan Novel segmented polymer and method of obtaining them
IL88003A (en) 1987-10-16 1992-11-15 Dainippon Pharmaceutical Co Quinoline derivatives,their preparation and pharmaceutical compositions containing them
US4916193A (en) 1987-12-17 1990-04-10 Allied-Signal Inc. Medical devices fabricated totally or in part from copolymers of recurring units derived from cyclic carbonates and lactides
NZ240846A (en) * 1990-12-06 1994-04-27 Hoechst Ag Dimeric bile acid derivatives; preparatory processes and pharmaceutical compositions
US5321099A (en) 1992-01-02 1994-06-14 The Dow Chemical Company Blends of semi-crystalline polyamides and polyesteramides
US5217493A (en) 1992-03-11 1993-06-08 Board Of Regents, The University Of Texas System Antibacterial coated medical implants
TW289020B (https=) 1993-05-08 1996-10-21 Hoechst Sktiengesellschaft
IT1270836B (it) 1993-10-27 1997-05-13 Archimica Spa Procedimento per la preparazione di rufloxacina e suoi sali
PT740650E (pt) * 1994-01-28 2004-10-29 Univ Kentucky Res Found Co-farmacos como um metodo de administracao controlada de farmacos
US6051576A (en) 1994-01-28 2000-04-18 University Of Kentucky Research Foundation Means to achieve sustained release of synergistic drugs by conjugation
US5387598A (en) 1994-04-13 1995-02-07 Rossignol; Jean-Francois Composition and galenic formulation suitable for combatting affections of the lower abdomen
US5578621A (en) 1994-09-08 1996-11-26 Romark Lab Lc Benzamide derivatives
PT755386E (pt) 1994-04-13 2002-11-29 Romark Lab Lc Derivado de benzamida composicoes contendo o referido derivado e sua utilizacao
US5965590A (en) 1994-09-08 1999-10-12 Romark Lab Lc Method for treatment of opportunistic infections with pharmaceutical compositions of tizoxanide and nitazoxanide
US5968961A (en) 1997-05-07 1999-10-19 Romark Laboratories, L.C. Pharmaceutical compositions of tizoxanide and nitazoxanide
US5859038A (en) 1994-09-08 1999-01-12 Romark Laboratories, L.C. Method for treatment of helicobacter pylori infections
MX9604483A (es) 1994-09-08 1998-02-28 Jean-Francois Rossignol Derivados de benzamida, composiciones que contienen dicho derivado y uso de las mismas.
US5856348A (en) 1994-09-08 1999-01-05 Romark Laboratories, L.C. Method for treatment of trematodes with pharmaceutical compositions of tizoxanide and nitazoxanide
DE19521642C2 (de) 1995-06-14 2000-11-09 Aesculap Ag & Co Kg Implantat, seine Verwendung in der Chirurgie und Verfahren zu seiner Herstellung
NZ313583A (en) 1995-08-03 1999-01-28 Paul J Santerre Fluoroligomer surface modifiers for polymers
DE69708461T2 (de) 1996-02-15 2002-06-27 Marc W. Mittelman Bioresponsive pharmakologisch aktive polymere und daraus hergestellte gegenstände
KR0176334B1 (ko) 1996-08-19 1999-04-01 박원훈 내인체 감염성 삽입금속표면의 코팅방법 및 그 치료기술
US5728751A (en) 1996-11-25 1998-03-17 Meadox Medicals, Inc. Bonding bio-active materials to substrate surfaces
ES2232687T3 (es) 1997-05-07 2005-06-01 Romark Laboratories, L.C. Composiciones farmaceuticas de tizoxanida y/o nitazoxanida.
NZ502358A (en) 1997-07-18 2002-11-26 Infimed Therapeutics Inc Hydrogel composition comprising a biologically active substance combined with a macromer
HN1998000106A (es) 1997-08-01 1999-01-08 Pfizer Prod Inc Composiciones parenterales de alatroflaxacino
PT1032605E (pt) 1997-09-10 2007-12-12 Univ Rutgers Polianidridos com produtos de degradação terapeuticamente úteis
US6468519B1 (en) 1997-09-10 2002-10-22 Rutgers, The State University Of New Jersey Polyanhydrides with biologically active degradation products
WO1999055396A1 (en) 1998-04-27 1999-11-04 Surmodics, Inc. Bioactive agent release coating
CA2340652C (en) 1998-08-20 2013-09-24 Cook Incorporated Coated implantable medical device comprising paclitaxel
CA2771263A1 (en) 2000-07-27 2002-02-07 Rutgers, The State University Therapeutic polyesters and polyamides
US6602915B2 (en) 2000-07-27 2003-08-05 Rutgers, The State University Of New Jersey Therapeutic azo-compounds for drug delivery
WO2002087586A1 (en) 2001-04-26 2002-11-07 Control Delivery Systems, Inc. Sustained release drug delivery system containing codrugs
CA2349989A1 (en) 2001-06-07 2002-12-07 Paul J. Santerre Bioactive surface modifiers for polymers and articles made therefrom
US20030158598A1 (en) 2001-09-17 2003-08-21 Control Delivery Systems, Inc. System for sustained-release delivery of anti-inflammatory agents from a coated medical device
BR0212897A (pt) 2001-09-21 2004-08-24 Univ Tulane Conjugados de análogos de somatostatina ou bombesina diagnóstica ou terapêutica e usos dos mesmos
AUPR879601A0 (en) 2001-11-09 2001-12-06 Biota Scientific Management Pty Ltd Novel chemical compounds and their use
US20050164994A1 (en) 2001-12-10 2005-07-28 Control Deliver Systems, Inc. Treatment of genitourinary tract disorders
CA2472188C (en) * 2002-01-18 2011-06-21 Control Delivery Systems, Inc. Polymeric gel system for the controlled delivery of codrugs
CA2493748A1 (en) 2002-08-14 2004-02-26 Medical College Of Georgia Research Institute, Inc. Methods and compositions for treatment of macular and retinal disease
TW200500067A (en) 2003-01-21 2005-01-01 Control Delivery Sys Inc Salts of codrugs and uses related thereto
WO2004112838A2 (en) 2003-05-21 2004-12-29 Control Delivery Systems, Inc. Codrugs of diclofenac
CA2553816A1 (en) 2004-01-15 2005-08-04 Warner Chilcott Company, Inc. Di-steroidal prodrugs of ethinyl estradiol
US20050220841A1 (en) 2004-04-06 2005-10-06 Dewitt David M Coating compositions for bioactive agents
US8147865B2 (en) 2004-04-30 2012-04-03 Allergan, Inc. Steroid-containing sustained release intraocular implants and related methods
CA2571320C (en) 2004-05-14 2016-05-10 Paul J. Santerre Polymeric coupling agents and pharmaceutically-active polymers made therefrom
WO2005110485A1 (en) 2004-05-14 2005-11-24 Interface Biologics Inc. Polymeric coupling agents and pharmaceutically-active polymers made therefrom
CA2467321A1 (en) 2004-05-14 2005-11-14 Paul J. Santerre Polymeric coupling agents and pharmaceutically-active polymers made therefrom
US8357385B2 (en) 2008-04-07 2013-01-22 Interface Biologics Inc. Combination therapy for the treatment of bacterial infections
US8461171B2 (en) 2010-02-09 2013-06-11 QRxPharma Ltd. Hybrid opioid compounds and compositions
WO2011120044A1 (en) 2010-03-26 2011-09-29 Duke University Conjugated neuroactive steroid compositions and methods of use
US8968626B2 (en) 2011-01-31 2015-03-03 Arsenal Medical, Inc. Electrospinning process for manufacture of multi-layered structures
WO2013106528A1 (en) 2012-01-10 2013-07-18 Virginia Commonwealth University Bivalent ligands for the treatment of neurological disorders
WO2014138425A1 (en) 2013-03-08 2014-09-12 Allergan, Inc. Cyclosporine a-steroid conjugates
DK3357522T3 (da) 2013-03-15 2020-01-27 Ripple Therapeutics Corp Coatet medicinsk genstand til lægemiddelsfrigivelse
LT3137081T (lt) 2014-04-28 2018-02-26 Orphomed, Inc. Buprenorfino dimeras ir jo naudojimas gydant virškinamojo trakto sutrikimus
EP3374369B1 (en) * 2015-11-12 2020-03-18 Board of Regents of the University of Nebraska Polyethylene glycol-conjugated glucocorticoid prodrugs and compositions and methods thereof
CN111971292B (zh) 2018-02-02 2024-12-13 波纹疗法公司 包含类固醇二聚体的玻璃制剂及其用途
WO2020154815A1 (en) 2019-02-01 2020-08-06 Ripple Therapeutics Corporation Crystalline forms of dexamethasone dimers and uses thereof
CN114599406A (zh) 2019-07-10 2022-06-07 波纹疗法公司 包含二聚类固醇前药的表面涂层和可植入装置及其用途
JP2022541341A (ja) 2019-07-25 2022-09-22 リップル セラピューティクス コーポレーション ステロイド二量体を含む物品と治療剤の送達におけるそれらの使用

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3663579A (en) * 1968-05-03 1972-05-16 Hoechst Ag Dimeric steroid-21-alkyl-carbonates and process for their manufacture
US20030118528A1 (en) * 2001-11-19 2003-06-26 Walters Kenneth A. Topical delivery of codrugs
WO2010062562A1 (en) * 2008-10-27 2010-06-03 The Trustees Of The University Of Pennsylvania Synthesis and use of cationic steroids for anti-inflammatory drug therapy

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Paryzek, Z. et al., 'A new approach to steroid dimers and macrocycles by the reaction of 3-chlorocarbonyl derivatives of bile acids with O, O-, N, N-, and S, S-dinucleophiles', Tetrahedron Letters. 2012, vol. 53(46), pages 6212-6215 *
Xue, M. et al., 'New dimeric cholesteryl-based A (LS) 2 gelators with remarkable gelling abilities: Organogel formation at room temperature', Journal of Colloid and Interface Science. 2011, vol. 361(2), pages 556-564 *

Also Published As

Publication number Publication date
US20210113457A1 (en) 2021-04-22
MX2020008017A (es) 2020-12-03
US11612567B2 (en) 2023-03-28
KR20200121816A (ko) 2020-10-26
US20190247311A1 (en) 2019-08-15
US20200113833A1 (en) 2020-04-16
EP3740494A1 (en) 2020-11-25
EP3740494A4 (en) 2021-11-03
AU2019214347A1 (en) 2020-08-20
US20230225975A1 (en) 2023-07-20
WO2019148293A1 (en) 2019-08-08
WO2019148291A1 (en) 2019-08-08
KR102952719B1 (ko) 2026-04-14
CA3087898A1 (en) 2019-08-08
CN111971292B (zh) 2024-12-13
US20210205222A1 (en) 2021-07-08
WO2019148294A1 (en) 2019-08-08
US20190275167A1 (en) 2019-09-12
US20250049719A1 (en) 2025-02-13
JP2021512852A (ja) 2021-05-20
US10959954B2 (en) 2021-03-30
JP7502186B2 (ja) 2024-06-18
US10588862B2 (en) 2020-03-17
US20200113834A1 (en) 2020-04-16
CN111971292A (zh) 2020-11-20
US20210030667A1 (en) 2021-02-04
US10945958B2 (en) 2021-03-16
US10632075B2 (en) 2020-04-28

Similar Documents

Publication Publication Date Title
AU2019214347B2 (en) Glass formulations comprising steroid dimers and uses thereof
JP2022541341A (ja) ステロイド二量体を含む物品と治療剤の送達におけるそれらの使用
BR112014027681B1 (pt) Nanocristais de propionato de fluticasona, composição tópica farmacêutica compreendendo os mesmos, seu uso e método de fabricação
EP3996764A1 (en) Surface coatings and implantable devices comprising dimeric steroid prodrugs, and uses thereof
JP2017514843A5 (https=)
US12473326B2 (en) Crystalline forms of dexamethasone dimers and uses thereof
JP2023524494A (ja) 眼障害を処置するためのヘテロ二量体組成物と方法
EP3265103B1 (en) Compositions comprising an aldosterone antagonist for use in treating dry eyes
US20250057962A1 (en) Processable compositions and use for the same
US20250074935A1 (en) Heterodimer compositions and methods for the treatment of ocular disorders
HK1252481B (zh) 疏水性治疗剂的制剂、其制备方法及应用

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)